Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-17-059823

SVP & Chief Scientific Officer sold 396,323 shares at an average $29.00 ($11,493,476)

  • SVP & Chief Scientific Officer acquired 396,323 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Doberstein Stephen K · SVP & Chief Scientific Officer

Table I: Non-derivative

6 lines
Date Transaction Shares Price Value Owned after D/I
2017-11-06 Exercise or conversion : show line 1 in the form +20,914 $9.53 $199,310 52,016 D
2017-11-06 Sale : show line 2 in the form −20,914 $24.98 $522,432 31,102 D
2017-11-07 Exercise or conversion : show line 3 in the form +75,409 $9.53 $718,648 106,511 D
2017-11-07 Sale : show line 4 in the form −75,409 $25.78 $1,944,044 31,102 D
2017-11-08 Exercise or conversion : show line 5 in the form +300,000 $9.53 $2,859,000 331,102 D
2017-11-08 Sale : show line 6 in the form −300,000 $30.09 $9,027,000 31,102 D
Open-market sales · 396,323 sh · avg $29.00 · $11,493,476

Table II: Derivative

3 lines
Date Transaction Shares Owned after D/I
2017-11-06 Exercise or conversion : show line 7 in the form Stock Option −20,914 375,409 D
2017-11-07 Exercise or conversion : show line 8 in the form Stock Option −75,409 300,000 D
2017-11-08 Exercise or conversion : show line 9 in the form Stock Option −300,000 0 D
Loading xslF345X03/doc4.xml…